Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ototoxicity of amikacin

R E Black, W K Lau, R J Weinstein

    Antimicrobial Agents and Chemotherapy
    |June 1, 1976
    PubMed
    Summary

    Amikacin ototoxicity can cause high-frequency hearing loss, particularly with higher doses and longer treatment durations. Monitoring amikacin blood levels and limiting therapy duration may prevent hearing damage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma.

    ESMO open·2025
    Same author

    Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.

    ESMO open·2022
    Same author

    Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas.

    British journal of cancer·2016
    Same author

    Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.

    Oncogene·2014
    Same author

    Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.

    Cell death & disease·2014
    Same author

    Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

    Oncogene·2014

    Area of Science:

    • Pharmacology
    • Ototoxicology
    • Nephrology

    Background:

    • Amikacin is an aminoglycoside antibiotic used for severe infections.
    • Aminoglycosides are known for potential ototoxicity and nephrotoxicity.
    • Monitoring is crucial to mitigate adverse effects.

    Purpose of the Study:

    • To evaluate the incidence and risk factors of amikacin-induced ototoxicity.
    • To assess the effectiveness of monitoring strategies for ototoxicity.

    Main Methods:

    • Prospective study of 77 patients receiving amikacin.
    • Monitoring included serial audiograms, serum creatinine, and amikacin blood levels.
    • Analysis of risk factors such as dose, duration, and previous aminoglycoside exposure.

    Main Results:

    • 24% of patients developed high-frequency hearing loss.
    • Higher total dose, longer duration, and prior aminoglycoside use were associated with hearing loss.
    • High peak (>32 µg/ml) and trough (>10 µg/ml) amikacin levels correlated with cochlear damage.

    Conclusions:

    • Amikacin ototoxicity, manifesting as high-frequency hearing loss, is a significant concern.
    • Monitoring blood levels and limiting treatment duration are key preventive strategies.
    • Early detection and intervention can potentially reduce hearing damage.

    Related Experiment Videos